Nomacopan

About Akari Therapeutics

Akari Therapeutics' mission is to develop and commercialize nomacopan, a first-in-class bispecific inhibitor of C5 and LTB4, for rare inflammatory disorders. Its primary achievement is advancing nomacopan into late-stage clinical trials for hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) and bullous pemphigoid. The company's strategy is intensely focused, dedicating all resources to generating pivotal clinical data to demonstrate proof-of-concept and unlock significant value. As a micro-cap biotech, its near-term fate is inextricably linked to the success of its lead program.

About Akari Therapeutics

Akari Therapeutics' mission is to develop and commercialize nomacopan, a first-in-class bispecific inhibitor of C5 and LTB4, for rare inflammatory disorders. Its primary achievement is advancing nomacopan into late-stage clinical trials for hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) and bullous pemphigoid. The company's strategy is intensely focused, dedicating all resources to generating pivotal clinical data to demonstrate proof-of-concept and unlock significant value. As a micro-cap biotech, its near-term fate is inextricably linked to the success of its lead program.

Therapeutic Areas